The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


Published online August 5, 2009
The Journal of Immunology, 2009, 183, 3160 -3169
Copyright © 2009 by The American Association of Immunologists, Inc.
doi:10.4049/jimmunol.0900385

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jimmunol.0900385v1
183/5/3160    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zhang, Z.
Right arrow Articles by Tsokos, G. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Z.
Right arrow Articles by Tsokos, G. C.

The Role of IL-23/IL-17 Axis in Lupus Nephritis1

Zheng Zhang2, Vasileios C. Kyttaris2 and George C. Tsokos3

Division of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215

T cells that express IL-17 infiltrate the kidneys of patients with systemic lupus erythematosus. A significant proportion of these cells are CD3+CD4CD8 double-negative T cells. In this study, we show that double-negative T cells from MRL/lpr mice express high amounts of IL-17 and that as disease progressively worsens, the expression of IL-17 and of IL-23 receptor in lymphocytes from these mice increases. Lymph node cells from lupus-prone mice, but not control mice, treated in vitro with IL-23 induce nephritis when transferred to non-autoimmune, lymphocyte-deficient Rag-1–/– mice. Kidney specimens from these recipient mice show significant Ig and complement deposition. The data indicate that an aberrantly active IL-23/IL-17 axis contributes to the development of nephritis in lupus-prone mice.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work is supported by National Institute of Health Grants R01 AI42269, R01 AI49954, and 1 K23 AR055672-01A1.

2 Z.Z. and V.C.K. contributed equally to this work.

3 Address correspondence and reprint requests to Dr. George C. Tsokos, Beth Israel Deaconess Medical Center, Division of Rheumatology, 330 Brookline Avenue, CLS-937, Boston, MA 02215. E-mail address: gtsokos{at}bidmc.harvard.edu

4 Abbreviations used in this paper: SLE, systemic lupus erythematosus; DNT, double-negative T cell; PAS, periodic acid-Schiff; DAPI, 4',6-diamidino-2-phenylindole.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.